Source: Pixabay.com

Orphan Drug Designation Granted to Three Active Moieties of INT230-6 for Soft Tissue Sarcoma (STS)

• Post author:Jessica Lynn
• Post published:September 7, 2023
• Post category:Soft Tissue Sarcoma

INT230-6, developed by clinical-stage biotechnology company Intensity Therapeutics (“Intensity”), is an investigational therapy comprising three moieties: cisplatin, SHAO-FA (a penetration enhancing molecule), and vinblastine sulfate. A moiety, in this sense,…

Continue Reading Orphan Drug Designation Granted to Three Active Moieties of INT230-6 for Soft Tissue Sarcoma (STS)

Photo by Emilio Garcia on Unsplash

Teen Raises £4K for Cancer Charity After Dad’s GIST Diagnosis

• Post author:Jessica Lynn
• Post published:July 22, 2023
• Post category:Gastrointestinal Stromal Tumors

In 2019, the Baird family, living in Scotland, received news that nobody wants to hear. Michael, the family patriarch, was diagnosed with a gastrointestinal stromal tumor (GIST), an uncommon tumor…

Continue Reading Teen Raises £4K for Cancer Charity After Dad’s GIST Diagnosis

source: shutterstock.com

Rare Community Profiles: Their Daughter’s Rare Disease Empowered the Traller Family to Advocate for ASPS Awareness and Research

• Post author:Jessica Lynn
• Post published:April 12, 2023
• Post category:Alveolar soft part sarcoma/Sarcoma/Soft Tissue Sarcoma

Rare Community Profiles     Rare Community Profiles is a new Patient Worthy article series of long-form interviews featuring various stakeholders in the rare disease community, such as patients, their…

Continue Reading Rare Community Profiles: Their Daughter’s Rare Disease Empowered the Traller Family to Advocate for ASPS Awareness and Research

source: pixabay.com

A Mom’s Sciatic Pain Turned Out to Be Liposarcoma

• Post author:Jessica Lynn
• Post published:March 9, 2023
• Post category:Liposarcoma

At first, 52-year-old Lisa Wolff thought that she was dealing with sciatic pain. The pain was sometimes dull, sometimes burning, but generally manageable. When the pain became too much to…

Continue Reading A Mom’s Sciatic Pain Turned Out to Be Liposarcoma

source: shutterstock.com

ICYMI: FDA Approves Tecentriq for Alveolar Soft Part Sarcoma

• Post author:Jessica Lynn
• Post published:January 9, 2023
• Post category:Alveolar soft part sarcoma

  While alveolar soft part sarcoma (ASPS) is considered to be relatively slow-growing, it is necessary to carefully manage this rare soft tissue sarcoma to avoid metastasizing. Surgery is one…

Continue Reading ICYMI: FDA Approves Tecentriq for Alveolar Soft Part Sarcoma

Source: Pixabay.com

Positive Interim Data Available on Sotigalimab-Doxorubicin Combo for Liposarcoma

• Post author:Jessica Lynn
• Post published:December 23, 2022
• Post category:Liposarcoma

  In a mid-November 2022 news release from biopharmaceutical company Apexigen, Inc., the company shared that positive interim results were available from a Phase 2 study evaluating sotigalimab, in conjunction…

Continue Reading Positive Interim Data Available on Sotigalimab-Doxorubicin Combo for Liposarcoma

July 13th is GIST Awareness Day!

• Post author:Jessica Lynn
• Post published:July 11, 2022
• Post category:Gastrointestinal Stromal Tumors

Did you know that July is widely considered to be Sarcoma Awareness Month? During this month, many stakeholders - from patients to researchers - aim to raise awareness of sarcomas,…

Continue Reading July 13th is GIST Awareness Day!

https://unsplash.com/photos/tV-RX0beDp8

Ilixadencel for GISTs Granted Orphan Drug Designation

• Post author:Jessica Lynn
• Post published:June 21, 2022
• Post category:Gastrointestinal Stromal Tumors

In the United States, the FDA grants Orphan Drug designation to drugs or biologics intended to treat, prevent, or diagnose rare diseases or conditions. Do you know what makes a…

Continue Reading Ilixadencel for GISTs Granted Orphan Drug Designation

Photo by National Cancer Institute on Unsplash

Veyonda for STS Granted Orphan Drug Designation

• Post author:Jessica Lynn
• Post published:April 15, 2022
• Post category:Soft Tissue Sarcoma

In the United States, Orphan Drug designation is granted by the FDA to drugs or biologics intended to treat, prevent, or diagnose rare diseases or conditions. “Rare” is defined as…

Continue Reading Veyonda for STS Granted Orphan Drug Designation

source: shutterstock

A Fusion Gene Could Better Identify and Diagnose Extraskeletal Myxoid Chondrosarcoma

• Post author:Jessica Lynn
• Post published:April 7, 2022
• Post category:Chondrosarcoma

  When two previously independent genes join together, and begin transcribing and translating as if they were one, this is known as a fusion gene. Fusion genes have previously been…

Continue Reading A Fusion Gene Could Better Identify and Diagnose Extraskeletal Myxoid Chondrosarcoma

stevepb / Pixabay

ICYMI: QINLOCK Approved in UK for GISTs

• Post author:Jessica Lynn
• Post published:January 21, 2022
• Post category:Gastrointestinal Stromal Tumors

In late December 2021, biopharmaceutical company Deciphera Pharmaceuticals, Inc. ("Deciphera") shared that its therapy QINLOCK (ripretinib) was approved in the United Kingdom. The treatment is designed for adults with advanced…

Continue Reading ICYMI: QINLOCK Approved in UK for GISTs

source: pixabay.com

IMX-110 for Soft Tissue Sarcoma Earns Orphan Drug Designation

• Post author:Jessica Lynn
• Post published:October 7, 2021
• Post category:Soft Tissue Sarcoma

  To best address the needs of patients with rare diseases and rare cancers, additional treatment options are necessary. But developing these treatment options can be time-consuming and sometimes difficult.…

Continue Reading IMX-110 for Soft Tissue Sarcoma Earns Orphan Drug Designation

source: pixabay.com

Sotigalimab for STS Earns Orphan Drug Status

• Post author:Jessica Lynn
• Post published:August 9, 2021
• Post category:Soft Tissue Sarcoma

Orphan drug designation is granted in the United States to expedite the development and review of drugs and biologics intended to treat patients with rare conditions (over 200,000 Americans). Once…

Continue Reading Sotigalimab for STS Earns Orphan Drug Status

DarkoStojanovic / Pixabay

New ASTRO Clinical Guideline Shares Insights on Radiation for STS

• Post author:Jessica Lynn
• Post published:August 3, 2021
• Post category:Soft Tissue Sarcoma

  Clinical guidelines are often used to improve patient treatment. These guidelines use evidence reviews, as well as an examination of other standards-of-care, to optimize patient care and outcomes. According…

Continue Reading New ASTRO Clinical Guideline Shares Insights on Radiation for STS

source: pixabay.com

Envafolimab for Soft Tissue Sarcoma Granted Orphan Drug Status

• Post author:Jessica Lynn
• Post published:June 29, 2021
• Post category:Soft Tissue Sarcoma

An Orphan Drug designation is granted to drugs or biologics intended to treat patients with rare diseases or conditions, affecting less than 200,000 Americans. Because it can sometimes be difficult…

Continue Reading Envafolimab for Soft Tissue Sarcoma Granted Orphan Drug Status

Photo by Robina Weermeijer on Unsplash

Annamycin for STS Lung Metastases Granted Fast Track Designation

• Post author:Jessica Lynn
• Post published:April 15, 2021
• Post category:Soft Tissue Sarcoma

In late March 2021, the FDA gave Fast Track designation to annamycin. The treatment, initially developed for patients with acute myeloid leukemia (AML), is now being explored for patients with…

Continue Reading Annamycin for STS Lung Metastases Granted Fast Track Designation

source: pixabay.com

Sarcoma Patients Need Specialized Expert Care

• Post author:Trudy Horsting
• Post published:March 4, 2021
• Post category:Soft Tissue Sarcoma

Sarcoma Sarcoma is a cancer that accounts for 1% of all adult cancers. It can affect individuals of any age and can impact any part of the body. It grows…

Continue Reading Sarcoma Patients Need Specialized Expert Care

TBIT / Pixabay

Polish Agency Awarded Grant for Annamycin Clinical Trial for STS

• Post author:Jessica Lynn
• Post published:February 15, 2021
• Post category:Rhabdomyosarcoma- embryonal/Soft Tissue Sarcoma

In a recent press release, pharmaceutical company Moleculin Biotech, Inc. ("Moleculin") shared a recent advance in the sphere of medical and health research. Agencja Badań Medycznych, a Polish agency which contributes…

Continue Reading Polish Agency Awarded Grant for Annamycin Clinical Trial for STS

source: pixabay.com

Experimental Treatment Could be Useful in Numerous Rare and Deadly Cancers

• Post author:Rose Duesterwald
• Post published:January 14, 2021
• Post category:Acute Myeloid Leukemia/Burkitt's lymphoma/Myelodysplastic syndromes/Pancreatic Cancer/Peripheral T-cell lymphoma

While novel treatments have been rapidly emerging onto the drug scene, new treatment options for pancreatic cancer have fallen behind. But now, according to OncLive’s interview with Dr. P.A. Philip,…

Continue Reading Experimental Treatment Could be Useful in Numerous Rare and Deadly Cancers

A New Investigative Therapy for Multiple Myeloma Holds Promise

• Post author:Trudy Horsting
• Post published:October 2, 2020
• Post category:Multiple Myeloma/Rare Disease

Damian Green from the University of Washington is the Principal Investigator for a new research project in multiple myeloma. This project is thanks to a research agreement between the Fred…

Continue Reading A New Investigative Therapy for Multiple Myeloma Holds Promise

source: pixabay.com

Next Generational Sequencing: Imaging Non-GIST Sarcoma Tumors

• Post author:Rose Duesterwald
• Post published:April 29, 2020
• Post category:Rare Disease/Soft Tissue Sarcoma

  An earlier online article in JCO Precision Oncology presents a study of next-generation sequencing (NGS) as it applies to molecular profiling of non-gastrointestinal stromal (GIST) soft tissue sarcomas .…

Continue Reading Next Generational Sequencing: Imaging Non-GIST Sarcoma Tumors

source: pixabay.com

Study Tests Combination Treatment for Advanced Soft Tissue Sarcoma

• Post author:James Moore
• Post published:March 17, 2020
• Post category:Rare Disease/Soft Tissue Sarcoma

According to a story from Hindawi, a recent study tested a combination treatment for patients with metastatic or locally advanced soft tissue sarcoma. Outcomes for these patients are poor if…

Continue Reading Study Tests Combination Treatment for Advanced Soft Tissue Sarcoma

British Science Journal Authors Voice Concerns Over Low Standards Supporting Cancer Drugs

• Post author:Rose Duesterwald
• Post published:September 24, 2019
• Post category:Cancer/Multiple Myeloma/Soft Tissue Sarcoma

  Fierce Biotech recently focused on a report by The BMJ, a British science journal, on the validity of clinical trials which are critical to decision making by patients and…

Continue Reading British Science Journal Authors Voice Concerns Over Low Standards Supporting Cancer Drugs

Press Release: ASCO Names Advance of the Year: Progress in Treating Rare Cancers

• Post author:Patient Worthy Contributor
• Post published:February 1, 2019
• Post category:Neuroendocrine Tumor

Progress Report Debuts ASCO’s Research Priorities for the Cancer Community, Emphasizes Impact of Federal Funding FOR IMMEDIATE RELEASE January 31, 2019 Ashley Yum 571-483-1376 [email protected]   ALEXANDRIA, Va. — Over the…

Continue Reading Press Release: ASCO Names Advance of the Year: Progress in Treating Rare Cancers

stevepb / Pixabay

Cancer Drug LARTRUVO Fails to Meet Primary Endpoint in Soft Tissue Sarcoma Clinical Trial

• Post author:James Moore
• Post published:January 24, 2019
• Post category:Soft Tissue Sarcoma

According to a story from PR Newswire, the international drug developer Eli Lilly and Company recently announced the results of a Phase 3 clinical trial testing the company's drug LARTRUVO…

Continue Reading Cancer Drug LARTRUVO Fails to Meet Primary Endpoint in Soft Tissue Sarcoma Clinical Trial